NeuroNOS

Biotechnology Research • • 1-10 Employees

Company overview

Headquarters	XX
Website	neuro-nos.com
NAICS	541714
Employees	1-10
Socials

Key Contact at NeuroNOS

Haitham Amal

Co-Founder and CSO

NeuroNOS Email Formats

NeuroNOS uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@neuro-nos.com), used 50% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@neuro-nos.com	50%
{first name}{last name}	johndoe@neuro-nos.com	50%

About NeuroNOS

NeuroNOS is pioneering a first-in-class therapy that targets the root biological causes of autism. Backed by two Nobel Laureates and granted FDA Orphan Drug Designation, we are developing a novel small molecule designed to restore brain function—not just manage symptoms. Our work is based on the groundbreaking discovery by Prof. Haitham Amal (Harvard/Boston Children’s), who uncovered the critical role of nitric oxide (NO) dysregulation in autism. This mechanism—now considered foundational in ASD research—involves oxidative and nitrosative stress, synaptic dysfunction, and disrupted brain metabolism. Our selective nNOS-targeted compound is engineered to correct this pathway. Led by research from MIT and Hebrew University, our preclinical data show near-complete restoration of behavioral and brain function in multiple ASD models. 🔹 FDA Orphan Drug Designation granted 🔹 First-in-human trials targeted for 2026 🔹 Strategic partnerships in progress We are proudly supported by Prof. Roger D. Kornberg (Nobel Laureate, Chemistry), Prof. Dan Shechtman (Nobel Laureate, Physics), and Prof. Amal as CSO. As we prepare for clinical trials, we welcome conversations with partners and investors who share our mission: to bring meaningful, mechanism-based therapies to individuals with autism—and ultimately, other brain disorders like Alzheimer's and glioblastoma. 🎥 Watch our story: https://youtu.be/DV9DNYzKSAI 📄 Publication: https://doi.org/10.1002/advs.202205783

NeuroNOS revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,100,000
Total funding	$2,000,000